Thiotepa-busulfan-fludarabine as a conditioning regimen for patients with myelofibrosis undergoing allogeneic hematopoietic transplantation: a single center experience

被引：10

作者：

Memoli, Mara ^{[1
,2
]}

Paviglianiti, Annalisa ^{[1
]}

Malard, Florent ^{[1
,3
,4
]}

Battipaglia, Giorgia ^{[1
,4
]}

Brissot, Eolia ^{[1
,3
,4
]}

Mediavilla, Clemence ^{[1
,4
]}

Bianchessi, Antonio ^{[1
,5
]}

Banet, Anne ^{[1
]}

Van de Wyngaert, Zoe ^{[1
]}

Ledraa, Tounes ^{[1
]}

Belhocine, Ramdane ^{[1
]}

Sestili, Simona ^{[1
]}

Lapusan, Simona ^{[1
]}

Hirsch, Pierre ^{[3
,4
,6
]}

Favale, Fabrizia ^{[3
,4
,6
]}

Boussaroque, Agathe ^{[3
,4
,6
]}

Bonnin, Agnes ^{[1
]}

Vekhoff, Anne ^{[1
]}

Legrand, Ollivier ^{[1
,3
,4
]}

Mohty, Mohamad ^{[1
,3
,4
]}

Dulery, Remy ^{[1
,3
,4
]}

机构：

[1] St Antoine Hosp, AP HP, Dept Hematol & Cellular Therapy, 184 Rue Faubourg St Antoine, F-75012 Paris, France

[2] Univ Naples Federico II, Hematol & Hematopoiet Stem Cell Transplant Ctr, Dept Med & Surg, Naples, Italy

[3] INSERM, UMRs 938, Paris, France

[4] Sorbonne Univ, Hop St Antoine, AP HP, Paris, France

[5] Univ Pavia, Dept Mol Med, Pavia, Italy

[6] Hop St Antoine, AP HP, Serv Hematol Biol, Paris, France

来源：

LEUKEMIA & LYMPHOMA | 2021年 / 62卷 / 02期

关键词：

Thiotepa; busulfan; fludarabine; HSCT; TBF; myelofibrosis; STEM-CELL TRANSPLANTATION; CORD BLOOD TRANSPLANTATION; LEUKEMIA WORKING PARTY; HAPLOIDENTICAL TRANSPLANTATION; EUROPEAN-SOCIETY; RISK-FACTORS; MARROW; SPLENECTOMY; RUXOLITINIB; MANAGEMENT;

D O I：

10.1080/10428194.2020.1827246

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

We assessed the outcomes associated with thiotepa, busulfan and fludarabine (TBF) conditioning regimen in a cohort of 29 consecutive patients allografted for myelofibrosis (MF). The median age was 56 (range 42-70) years. According to the refined Dynamic International Prognostic Scoring System (DIPSS-plus), 15 (52%) patients were classified as high risk. Graft source was peripheral blood stem cells in 27 patients. Donor type was HLA-matched related (n = 5), matched unrelated (n = 16), mismatched unrelated (n = 1), and haploidentical (n = 7). All but 2 patients engrafted. The cumulative incidence (CI) of grade II-IV acute graft-versus-host disease (GVHD) was 21% (95% CI, 10-42) at day 100. The CI of chronic GVHD was 39% (95% CI, 23-65) at 3 years. The median follow-up period was 39 (range 14-60) months. Overall survival was 69% (95% CI, 50-83) at 3 years. No relapse was observed. TBF is a valid conditioning strategy in patients with MF.

引用

页码：419 / 427

页数：9

共 50 条

[41] Allogeneic Hematopoietic Stem Cell Transplantation for Primary Myelofibrosis: A 20-year Experience in a Single Center [J].

Seval, Guldane Cengiz ;

Bozdag, Sinem Civriz ;

Toprak, Selami Kocak ;

Yuksel, Meltem Kurt ;

Topcuoglu, Pervin ;

Arslan, Onder ;

Demirer, Taner ;

Gurman, Gunhan ;

Beksac, Meral ;

Ilhan, Osman ;

Ozcan, Muhit .

BALKAN MEDICAL JOURNAL, 2023, 40 (03) :197-204

[42] Treosulfan-fludarabine-thiotepa-based conditioning treatment before allogeneic hematopoietic stem cell transplantation for pediatric patients with hematological malignancies [J].

Kalwak, Krzysztof ;

Mielcarek, Monika ;

Patrick, Katharine ;

Styczynski, Jan ;

Bader, Peter ;

Corbacioglu, Selim ;

Burkhardt, Birgit ;

Sykora, Karl Walter ;

Drabko, Katarzyna ;

Gozdzik, Jolanta ;

Fagioli, Franca ;

Greil, Johann ;

Gruhn, Bernd ;

Beier, Rita ;

Locatelli, Franco ;

Mueller, Ingo ;

Schlegel, Paul Gerhardt ;

Sedlacek, Petr ;

Stachel, Klaus Daniel ;

Hemmelmann, Claudia ;

Moeller, Ann-Kristin ;

Baumgart, Joachim ;

Vora, Ajay .

BONE MARROW TRANSPLANTATION, 2020, 55 (10) :1996-2007

[43] Busulfan plus fludarabine compared with busulfan plus cyclophosphamide as a conditioning regimen prior to hematopoietic stem cell transplantation in patients with hematologic neoplasms: a meta-analysis [J].

Lei, Xiao-Ru ;

Chen, Hong-Li ;

Wang, Fang-Xia ;

Bai, Ju ;

He, Ai-Li .

INTERNATIONAL JOURNAL OF CLINICAL AND EXPERIMENTAL MEDICINE, 2015, 8 (08) :12064-12075

[44] Allogeneic hematopoietic cell transplantation for myelofibrosis using fludarabine-, intravenous busulfan- and low-dose TBI-based conditioning [J].

Shanavas, M. ;

Messner, H. A. ;

Atenafu, E. G. ;

Kim, D. H. ;

Kuruvilla, J. ;

Lipton, J. H. ;

Uhm, J. ;

Seftel, M. ;

Alam, N. ;

Gupta, V. .

BONE MARROW TRANSPLANTATION, 2014, 49 (09) :1162-1169

[45] Population Pharmacokinetics of Busulfan and Its Metabolite Sulfolane in Patients with Myelofibrosis Undergoing Hematopoietic Stem Cell Transplantation [J].

Dadkhah, Adrin ;

Wicha, Sebastian Georg ;

Kroeger, Nicolaus ;

Mueller, Alexander ;

Pfaffendorf, Christoph ;

Riedner, Maria ;

Badbaran, Anita ;

Fehse, Boris ;

Langebrake, Claudia .

PHARMACEUTICS, 2022, 14 (06)

[46] Autologous transplantation for relapsed non-Hodgkin's lymphoma using intravenous busulfan and cyclophosphamide as conditioning regimen: a single center experience [J].

Escalon, M. P. ;

Stefanovic, A. ;

Venkatraman, A. ;

Pereira, D. ;

Santos, E. S. ;

Goodman, M. ;

Byrnes, J. J. ;

Fernandez, H. F. .

BONE MARROW TRANSPLANTATION, 2009, 44 (02) :89-96

[47] Targeted Marrow Irradiation Intensification of Reduced-Intensity Fludarabine/Busulfan Conditioning for Allogeneic Hematopoietic Stem Cell Transplantation [J].

Ali, Naveed ;

Sharma, Ashish Arunkumar ;

Pires de Rezende, Ana Carolina ;

Otegbeye, Folashade ;

Latif, Bilal Muhammad ;

Kerbauy, Mariana Nassif ;

Cooper, Brenda W. ;

Sanchez, Gabriela ;

Metheny, Leland ;

Bal, Saswat K. ;

Sakuraba, Roberto ;

Tomlinson, Benjamin K. ;

Boughan, Kirsten M. ;

Kerbauy, Lucila ;

Malek, Ehsan ;

Ribeiro, Andreza Feitosa ;

Gallogly, Molly ;

Mansur, David ;

Pereira, Gisele ;

Weltman, Eduardo ;

Sekaly, Rafick-Pierre ;

de Lima, Marcos ;

Caimi, Paolo F. ;

Hamerschlak, Nelson .

TRANSPLANTATION AND CELLULAR THERAPY, 2022, 28 (07) :370.e1-370.e10

[48] Thiotepa/cyclophosphamide/TBI as a conditioning regimen for allogeneic hematopoietic stem cell transplantation in patients aged 50 years and over [J].

Fujimaki, Katsumichi ;

Tanaka, Masatsugu ;

Takasaki, Hirotaka ;

Hyo, Rie ;

Kawano, Tomoko ;

Sakai, Rika ;

Fujita, Hiroyuki ;

Fujisawa, Shin ;

Kanamori, Heiwa ;

Maruta, Atsuo ;

Ishigatsubo, Yoshiaki .

INTERNAL MEDICINE, 2008, 47 (05) :379-383

[49] Treosulfan is a safe and effective alternative to busulfan for conditioning in adult allogeneic HSCT patients: Data from a single center [J].

Uzay, Ant ;

Gundogdu, Yasemin ;

Kosan, Baris ;

Yetis, Tugba ;

Karti, S. Sami .

CANCER MEDICINE, 2024, 13 (10)

[50] Reduced-intensity conditioning allogeneic hematopoietic cell transplantation using oral fludarabine as part of the conditioning regimen [J].

Delgado, J. ;

Marco, A. ;

Moreno, E. ;

Pinana, J. L. ;

Valcarcel, D. ;

Martino, R. ;

Briones, J. ;

Sureda, A. ;

Brunet, S. ;

Sierra, J. .

CYTOTHERAPY, 2009, 11 (03) :356-361

← 1 2 3 4 5 →